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A New Monocyte Chemotactic Protein-1/
Chemokine CC Motif Ligand-2 Competitor
Limiting Neointima Formation and
Myocardial Ischemia/Reperfusion Injury in Mice
Elisa A. Liehn, MD, PHD,*†‡ Anna-Maria Piccinini, PHD,§ Rory R. Koenen, PHD,*
Oliver Soehnlein, MD, PHD,* Tiziana Adage, PHD,§ Roxana Fatu, MD,* Adelina Curaj, BS,*¶
Alexandra Popescu, BS,*¶ Alma Zernecke, MD,*# Andreas J. Kungl, PHD,§ Christian Weber, MD*‡
Aachen and Würzburg, Germany; Graz, Austria; Maastricht, the Netherlands; and Bucharest, Romania
Objectives A nonagonist monocyte chemotactic protein-1 (MCP-1/CCL2) mutant (PA508) with increased affinity for glycos-
aminoglycans and thus competing with CCL2 was evaluated as a candidate for preventing neointima formation
or myocardial ischemia/reperfusion injury.
Background Myocardial infarction (MI) remains a major cause of death worldwide despite improved interventional and thera-
peutic options. Therefore, the discovery of drugs that limit restenosis after intervention and post-MI damage re-
mains an important challenge.
Methods The function of PA508 was assessed in functional assays in vitro and in mouse models of wire-induced neoin-
tima formation and experimental MI.
Results PA508 was functionally inactive in CC chemokine receptor 2 (CCR2) binding and calcium influx but inhibited
monocyte chemotaxis or transendothelial migration toward CCL2, suggesting that it interferes with CCL2 presen-
tation. In wild-type but not CCR2-deficient mice, PA508 reduced inflammatory leukocyte recruitment without
affecting differential leukocyte counts, CCL2 levels, organ function, or morphology, indicating that it specifically
attenuates the CCL2-CCR2 axis. Compared with vehicle, daily intraperitoneal injection of PA508 significantly
(p  0.05, n  5) reduced neointimal plaque area and mononuclear cell infiltration in carotid arteries of hyper-
lipidemic apolipoprotein E-deficient mice while increasing smooth muscle cell content. In C57Bl/6J mice that
underwent myocardial ischemia/reperfusion, treatment with PA508 significantly reduced infarction size, mono-
cyte infiltration, and collagen and myofibroblast content in the infarction area and preserved heart function com-
pared with vehicle (p  0.05, n  4 to 8).
Conclusions Here we demonstrate that administration of a rationally designed CCL2 competitor reduced inflammatory mono-
cyte recruitment, limited neointimal hyperplasia, and attenuated myocardial ischemia/reperfusion injury in mice
and could therefore be envisioned as a combined therapeutic approach for restenosis and MI. (J Am Coll Car-
diol 2010;56:1847–57) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.066k
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the development of atherosclerosis
(5,6), but are also involved in myo-
cardial healing and scar formation
after MI (1,7,8). Chemokines have
highly conserved and well-defined
structures tailored to their function
as inflammatory mediators. In par-
ticular, most chemokines can form
multimeric structures, and specific
amino acid motifs confer high
affinity for glycosaminoglycans
(GAGs), allowing effective pre-
sentation on the surface of vascu-
ar cells. Chemokines are functionally intolerant to modi-
cations of the N terminus, a property that has been exploited
or regulated on activation, T-cell expressed, and secreted
RANTES/CCL5) to create the antagonist Met-CCL5 (9).
utations that affect oligomerization and/or GAG interaction
f chemokines have also generated chemokine variants with
ntagonistic properties (10,11).
The CC motif chemokine monocyte chemoattractant
rotein (MCP)-1/CCL2 is a potent mononuclear cell che-
oattractant involved in various diseases characterized by
onocyte-rich leukocyte infiltrates (12). CCL2 can directly
nfluence wound angiogenesis by mediating endothelial cell
igration (13) and can modulate fibrous tissue deposition
y stimulating extracellular matrix production and differen-
iation of fibroblasts toward a myofibroblast-like phenotype
14,15). CCL2 is also essential in the development of
estenotic changes after coronary intervention by mediating
onocyte infiltration and their subsequent activation (16).
ice that lack CCR2, the receptor for CCL2, show a
arked reduction in neointima formation, monocyte re-
ruitment, and neointimal macrophage content after arterial
njury (17). After ischemia/reperfusion (I/R) injury, these
ice exhibit a decrease in macrophage infiltration and
nfarct size compared with wild-type mice (15,18). Simi-
arly, CCL2-deficient mice display a decreased and de-
ayed macrophage infiltration and myofibroblast accumu-
ation associated with an improvement of left ventricular
LV) dysfunction and regional hypocontractility after MI
19,20). In line with these findings, CCL2 can induce a
ovel transcription factor that causes cardiac cell death
nd ventricular dysfunction (21). Hence, pharmacological
nhibition of CCL2 might represent an attractive ap-
roach to prevent detrimental vascular remodeling and to
ttenuate damage after MI. Indeed, the inhibition of
CL2 by an antibody resulted in reduction of athero-
clerosis and inflammation in Apoe/ mice, inducing a
table atherosclerotic plaque phenotype (22) and thus
emonstrating the feasibility of this approach. However,
ntibodies are large proteins difficult to be economically
roduced in sufficient amounts, need to be humanized,
nd carry the risk of undesired binding to other antigens,
Abbreviations
and Acronyms
CCL  chemokine CC
motif ligand
CCR  chemokine CC
motif receptor
GAG  glycosaminoglycan
I/R  ischemia/reperfusion
LV  left ventricular
MCP  monocyte
chemotactic protein
MI  myocardial infarctionhich may affect safety of long-term treatment. oThe purpose of our study was to explore beneficial effects
f a recombinant CCL2 competitor (PA508), a CCR2-
ctivation incompetent variant of CCL2, which was engi-
eered to have an increased affinity for GAGs, as a novel
herapeutic approach for the prevention of neointimal for-
ation and myocardial I/R injury in mice.
ethods
eneration of PA508. The amino acid mutations in hu-
an CCL2 complementary DNA were introduced by
tandard molecular cloning (23).
urface plasmon resonance. Equilibrium binding of
CL2 and PA508 to heparin pentasaccharide (Sanofi-
ventis, Paris, France) was determined (24,25) and used for
catchard plot analysis and calculation of dissociation con-
tants (kilodaltons).
alcium mobilization. Calcium transients in Fluo-4–
abeled THP-1 cells were recorded in a microplate reader.
fter baseline measurement, cells were stimulated with
2O (control), CCL2, or PA508 (50 ng/ml).
hemotaxis and transendothelial migration. The effects
f PA508 on THP-1 cell migration toward CCL2 for 2 h
t 37°C were assessed using 5-m Transwell filters seeded
ithout or with human umbilical vein endothelial cells and
nalyzed by flow cytometry.
hemokine receptor binding studies. PA508 binding
tudies to CCR2-transfected cells were performed using
25I-CCL2 displaced by PA508 or Met-CCL2 in compar-
son with wtCCL2 in Hank’s balanced salt solution buffer.
harmacokinetics of PA508. Female Balb/cOlaHsd mice
Harlan Laboratories, Horst, Belgium) were injected intra-
eritoneally with Met-CCL2 or PA508 20 g per mouse.
erum concentrations of Met-CCL2 or PA508 were deter-
ined by species-specific enzyme-linked immunosorbant
ssay for human CCL2 (Anogen, Yes Biotech Laboratories
td., Mississauga, Ontario, Canada) at various time points.
A508 treatment of mice. Mice were treated intraperito-
eally with PA508 (0, 1, 5, or 10 g in phosphate-buffered
aline). All animal experiments and study protocols were
pproved by local authorities, complying with German
nimal protection laws.
xamination of PA508-treated mice. Venous blood was
btained from C57Bl/6J mice before treatment (6 mice per
roup) and at 1, 3, and 8 days and assayed for alanine-
minotransferase, creatinine, and CCL2 levels. Organs were
arvested for histological analysis. Blood cells were analyzed
y flow cytometry (Becton Dickinson, Franklin Lakes, New
ersey).
eukocyte recruitment in vivo. An air-pouch model (26)
as performed in C57Bl/6J (8 per group) or CCR2/
ice (4 per group) treated intravenously with phosphate-
uffered saline, PA508 (10 g), or heat-inactivated PA508
HI-PA508) (10 g, n  4).
ire-injury and ex vivo perfusion models. Eight-week-ld Apoe/ or Ccr2/Apoe/ mice underwent carotid
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A508 1 day before injury and daily for 3 weeks. Neointi-
al areas, reported as a percentage of external elastic lamina
nd cell content, were analyzed by histomorphometry. Some
rteries were perfused ex vivo with MonoMac6 cells 1 day
ost-injury (29).
urine model of myocardial I/R. Eight-week-old male
57Bl/6J mice underwent sham or coronary occlusion and
eperfusion (19,30). Mice were treated with vehicle or
Figure 1 Design and Functional Characterization of PA508
(A) Sequence comparison of human CCL2 and PA508 with modified residues is sh
of CCL2 (solid line) and PA508 (dashed line) perfused over immobilized heparin p
squares) binding to immobilized heparin pentasaccharide. Receptor binding compe
(E), compound concentrations (M) were converted to negative logarithms. (F) Calc
in Fluo-4–labeled THP-1 cells. Transwell filter chemotaxis (G) or transendothelial m
monocytic THP-1 cells toward buffer, PA508 (100 ng/ml), or CCL2 (50 ng/ml) in th
Transwell filter.A508 10 min after ligation, 2 h after reperfusion, and daily cor 7 days and analyzed for myocardial function, infarction
ize, and cell content by echocardiography, Millar pressure
atheter, Langendorff perfusion, and histomorphometry
see Online Appendix Methods section for details).
tatistical analysis. Data represent mean  SEM and were
nalyzed by Student t test, 1-way analysis of variance, or
ruskal-Wallis test followed by Newman-Keuls or Dunn’s
ost-test, respectively, using Prism4 software (GraphPad,
a Jolla, California), as appropriate. A p value 0.05 was
n bold type. (B) Normalized surface plasmon resonance sensorgrams of 500 nM
accharide. (C) Scatchard analysis of CCL2 (solid circles) and PA508 (solid
of radiolabeled 125I-CCL2 from CCR2-transfected cells by CCL2 (D) or PA508
gnaling of CCL2 (triangles), PA508 (inverted triangles), or H2O (open squares)
n across unstimulated human umbilical vein endothelial cell monolayers (H) of
ence or presence of PA508 (100 ng/ml) in the upper or lower chamber of theown i
entas
tition
ium si
igratio
e absonsidered significant.
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esign and functional characterization of PA508. To
btain a CCL2-based decoy protein that has increased
AG binding affinity and is deficient in CCR2 activation,
e introduced basic amino acids into the GAG binding site
f CCL2 besides the tyrosine 13 to alanine mutation, which
revents CCR2 activation (31) (i.e., the existing GAG
inding motif in the amino acids 21 to 24 region was
ngineered by mutating serine 21 and glutamine 23 into
ysine and arginine, respectively) (Fig. 1A). This gave rise to
A508, an inactive CCL2 mutant with increased GAG
inding affinity that could compete with natural CCL2 for
AG binding sites (23). Surface plasmon resonance re-
ealed the predicted increase in affinity of PA508 for
AGs, showing a markedly prolonged retention of PA508
n immobilized heparin pentasaccharide compared with
ild-type CCL2 (Fig. 1B). Scatchard analysis of these data
ielded an almost 20-fold increase in affinity of PA508 for
eparin with calculated dissociation constants (kilodaltons)
f 5.2  108 M for PA508 and 9.4  107 M for
ild-type CCL2 (Fig. 1C). Isothermal titration calorimetry
onfirmed increased affinity for chondroitin sulfate (data not
hown). Receptor binding assays demonstrated a 7,000-
old lower affinity of PA508 for CCR2, as evident by its
educed ability to compete with a radiolabeled tracer for
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Figure 2 Pharmacokinetics and Leukocyte Recruitment Inhibiti
Pharmacokinetic profiles of Met-CCL2 and PA508 after intraperitoneal administrati
nosorbent assay after 1, 15, and 30 min and 1, 2, 4, 18, and 24 h. Total leukocy
tor (TNF)- (10 ng/ml) after intravenous pre-treatment with phosphate-buffered sal
bars) or CCR2/ mice (open bars) (B) (mean  SEM, **p  0.001, 3 to 6 per
of PA508 and perfused with monocytic MonoMac6, showed a decreased dose-dep
control). (D) Representative images of adherent MonoMac6 cells in injured ex vivoinding to CCR2-transfected cells, with an IC50 of 6.6  A08 M compared with the IC50 value obtained for
tCCL2 of 8.9  1012 M (Figs. 1D and 1E). In this
etup, Met-CCL2 exhibited a similar IC50 value as PA508
data not shown), suggesting that N-terminal methionyla-
ion of CCL2 strongly impairs binding to CCR2. Func-
ional assays revealed that PA508 was inactive as a CCR2
gonist because, unlike CCL2, it neither induced calcium
nflux nor chemotaxis in monocytic cells (Figs. 1F to 1H).
espite impaired binding to CCR2, PA508 prevented
oth chemotaxis and transendothelial migration of
onocytic cells toward CCL2, when added to the top
hamber, implying that presentation of CCL2 on GAGs
recedes activation of CCR2 and that PA508 actively
nterferes with this process (Figs. 1G and 1H). PA508
id not affect transendothelial migration of monocytic
ells induced by other atherogenic chemokines (e.g.,
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he mouse. (A) Serum concentrations were determined by enzyme-linked immu-
nts in mouse air pouch fluids after treatment with vehicle or tumor necrosis fac-
ntrol), PA508 (10 g), or heat-inactivated (HI) PA508 (10 g) in wild-type (solid
ns  not significant. Injured carotid arteries (C), incubated with different doses
t adhesion of the monocytes (mean  SEM, 3 to 6 per group, *p  0.05 vs.
sed carotid arteries treated without or with PA508 (10 g).
harmacokinetic Parameters of Met-CCL2 and PA508Table 1 Pharmacokinetic Parameters of Met-CCL2 and PA508
Met-CCL2 PA508
Cmax, ng/ml 314 226
Tmax, h 1 1
t1/2, h 2.8 2.9
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CL2 (Online Fig. 1A).
harmacokinetics of PA508 and effects on leukocyte
ecruitment. Pharmacokinetic profiles of Met-CCL2 and
A508 were monitored by antigen measurement in serum
amples obtained at different time points after intraperito-
eal administration (20 g per mouse) (Fig. 2A). Met-
CL2 displayed a rapid passage to the blood circulation,
ith a peak level of 314 ng/ml (Cmax) at 1 h (tmax) and
lasma half-life of 2.8 h, similar to what has been reported
or native CCL2 (11). PA508 showed a comparable profile
ith a peak of 226 ng/ml (Cmax) reached at 1 h (tmax) and
plasma half-life of 2.9 h (Table 1). At 24 h, Met-CCL2
as detectable at 0.1 ng/ml, whereas PA508 was present at
.6 ng/ml. During an 8-day treatment with PA508 (10
g/day per mouse), total and differential leukocyte counts
id not undergo major variations compared with baseline
Table 2). The levels of endogenous CCL2 in serum were
ot influenced by treatment with PA508 (Online Fig. 1B),
o differences in alanine aminotransferase and creatinine
evels were observed (data not shown), and histological
nalysis of the lungs, liver, and kidneys did not reveal
bnormalities (Online Fig. 2).
To validate that PA508 acts as a CCL2 competitor in
ivo, its effect was assessed in a mouse air pouch model of
eukocyte recruitment. Injection of tumor necrosis factor-
esulted in a marked influx of leukocytes into the air pouch
uid that could be effectively reduced by pre-treating mice
ith an intravenous dose of PA508 (Fig. 2B). Administra-
ion of heat-inactivated PA508 or vehicle did not decrease
eukocyte recruitment. In CCR2/ mice, tumor necrosis
ell Counts of Leukocyte PopulationsTable 2 Cell Counts of Leukocyte Populations
Cell Type and
Time Point
Control
( 10,000/ml)
PA508 (10 g)
( 10,000/ml) p Value
Neutrophils
Day 0 61 28 (6) 73 29 (6) NS
Day 1 97 53 (6) 90 31 (6) NS
Day 3 110 63 (6) 95 35 (6) NS
Day 8 93 30 (6) 115 24 (5) NS
Monocytes
Day 0 15 4.3 (6) 17 5.1 (6) NS
Day 1 30 17 (6) 28 15 (6) NS
Day 3 25 7.6 (6) 38 7.8 (6) 0.05
Day 8 17 5.6 (6) 24 3.3 (5) 0.05
T cells
Day 0 229 61 (6) 243 106 (6) NS
Day 1 185 65 (6) 253 134 (6) NS
Day 3 269 88 (6) 260 63 (6) NS
Day 8 217 45 (6) 283 54 (6) 0.05
B cells
Day 0 280 106 (6) 284 120 (6) NS
Day 1 284 98 (6) 314 165 (6) NS
Day 3 367 190 (6) 325 75 (6) NS
Day 8 261 64 (6) 286 14 (6) NS
alues are mean  SD (n).actor-–induced leukocyte influx was impaired compared mith wild-type mice and equivalent to levels seen in PA508-
reated wild-type mice (Fig. 2B). Notably, treatment with
A508 did not attenuate leukocyte recruitment in CCR2/
ice, highlighting the specificity of the competitor in vivo.
njection of tumor necrosis factor- in air pouches of
ild-type mice markedly increased CCL2 levels in the
ouch fluids, when mice were pre-treated with vehicle or
eat-inactivated PA508 but not with PA508 (Online Fig.
C), likely reflecting reducing effects of leukocyte influx.
Endothelial damage is followed by a local coagulatory and
nflammatory response leading to deposition of platelets and
dhesion of mononuclear cells. Monocyte adhesion after
rterial injury is mediated by CCL2 present on activated
latelets (17). To investigate an inhibitory effect of PA508
n this setting, carotid arteries were injured and excised after
day, incubated with varying doses of PA508 (1, 5, and 10
g/ml), and perfused with monocytic cells ex vivo. We
ound a dose-dependent decrease in luminal monocyte
dhesion to injured carotid arteries (Figs. 2C and 2D). Our
esults establish the anti-inflammatory potential of PA508
nd its feasibility as a therapeutic agent in cardiovascular
athologies such as restenosis or MI.
ffects of PA508 on neointima formation after wire
njury. Next, we subjected Apoe/ mice treated with
A508 or vehicle to wire-induced endothelial denudation
njury of the carotid artery. Compared with vehicle-treated
ice, PA508 treatment resulted in a significant reduction
n neointima area in wire-injured arteries, as evident by
entachrome staining and morphometry (22.9  2.1% vs.
5.6  2.2% external elastic lamina (EEL) in controls,
 5, p  0.05) (Fig. 3A). No differences in the medial
rea were observed (data not shown). The decrease in
eointimal area was associated with changes in cell compo-
ition. The relative content of macrophages was significantly
iminished (5.8  2.0% vs. 25.2  1.5% in controls, n  5,
 0.05) (Fig. 3B), whereas smooth muscle cell content
as increased in the neointima of PA508-treated mice (24.2
2.6% vs. 14.5  3.3% in controls, n  5, p  0.05)
Fig. 3C) and luminal CD31 lining as a measure of
e-endothelialization was unaltered (data not shown). No
ifferences in endogenous CCL2 serum levels were observed
fter the 22-day treatment with PA508 compared with
ehicle (Online Fig. 1D). Neointimal CCL2 expression
fter 3 weeks was unaltered by PA508 (data not shown).
otably, PA508 failed to significantly reduce wire-induced
eointima formation in CCR2-deficient Apoe/ mice,
onfirming its specificity for CCR2 (Online Fig. 1E).
aken together, competition for GAG binding of CCL2
ith the nonagonist PA508 markedly reduces neointima
ormation and generates a more stable plaque phenotype
ith reduced macrophage infiltration.
ffects of PA508 in a model of myocardial I/R. The
ajor complication of coronary stenosis with unstable
laques is MI causing substantial tissue damage in part due
o monocyte infiltration. Thus, we hypothesized that ad-
inistration of PA508 might reduce myocardial damage
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Novel CCL2 Competitor for Cardiovascular Therapy November 23, 2010:1847–57fter MI. Mice underwent myocardial I/R and were treated
ith varying doses of PA508. After 7 days, isolated heart
tudies according to Langendorff were performed under
onstant perfusion pressure and electrical stimulation (600/
in constant heart rate). We observed an impairment in LV
unction in wild-type mice, whereas LV function was
ignificantly preserved in mice treated with 10-g PA508
54.2  2.4 mm Hg vs. 33.7  5.4 mm Hg in controls,
 5 to 6, p  0.05) (Fig. 4A). Positive (2,519  238 mm
g/s vs. 1,377  215 mm Hg/s in controls, n  5 to 6,
 0.05) and negative pressures (1,602  172 mm Hg/s
s.939 122 mm Hg/s in controls, n 5 to 6, p 0.05)
erived over time displayed similar patterns (Figs.
B and 4C), indicating a marked improvement of contrac-
ility and relaxation in the hearts of PA508-treated mice.
Figure 3 Morphometry and Cell Content in Injured Arteries
(A) Representative pentachrome-stained sections of carotid arteries 3 weeks afte
with PA508. Quantitative immunohistochemistry reveals that the relative content o
muscle cell content (C) was increased in PA508-treated mice (A to C: all mean oreover, mice treated with 5 or 10 g of PA508 displayed inotable improvement in these parameters in response to
drenergic stimulation with dobutamine, unveiling a dose-
ependent and even more apparent efficacy of the compet-
tor under these conditions (Figs. 4B and 4C). Coronary
ow analysis did not reveal differences between the groups.
e verified these results by performing echocardiography
nd intraventricular measurements in control mice and mice
reated with PA508 at 10 g. Both groups compensated for
he loss of cardiac mass and produced the same cardiac
utput; however, PA508-treated mice showed a better
reserved cardiac function compared with control mice
ejection fraction 51.8  1.2% vs. 40.4  3.9%, n  4 to 5,
 0.05) (Table 3). In vivo measurements using the Millar
ressure Transducer Catheter confirmed a significantly
reserved heart function (86 6 mm Hg vs. 64 5 mm Hg
njury of Apoe/ mice show a decrease in neointima formation in mice treated
ophages (B) in the neointima was reduced, whereas the neointimal smooth
5 per group, *p  0.05 vs. control). EEL  external elastic lamina.r wire i
f macr
SEM,n controls, n 4 to 5, p 0.05) and improved contractility
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ontrols, n 4 to 5, p 0.05) in PA508-treated mice. Due
o anesthesia with ketamine/xylazine, the heart rate was
ecreased in this experiment but comparable between con-
rol and PA508-treated mice (Table 3). These data con-
incingly demonstrate a favorable effect of PA508 on heart
unction after I/R injury.
Histomorphometric analysis revealed a significant reduc-
ion of MI size in all PA508-treated groups compared with
ehicle-treated controls (6.8  0.5% at 10 g, 7.5  0.5%
t 5 g, and 11.3  5.4% at 1 g in the PA508 group vs.
6.5  3.4% of LV area in controls, n  5 to 6, p  0.05)
Fig. 5A). Monocyte infiltration was markedly but dose-
ependently reduced in all groups, indicating a high efficacy
f PA508 (51  17 cells/mm2 at 1 g, 25  6 cells/mm2 at
g, and 36  7 cells/mm2 at 10 g vs. 204  68
Figure 4 Functional Assessment After Myocardial Ischemia/Re
Hearts collected 1 week after ischemia/reperfusion were studied in a Langendorff
derived pressure (B), and minimum time-derived pressure (C) show a better prese
Administration of dobutamine led to significant improvement of physiological param
are reported as mean  SEM (6 to 8 mice per group, *p  0.05 vs. control). dPdells/mm2 in controls, n  5 to 6, p  0.05) (Fig. 5B). This Puggests that attenuation of monocyte infiltration was a
ajor mechanism contributing to preserved myocardial
unction. Myofibroblast content was found to be decreased
nly at the highest concentration of PA508 (935  416
ells/mm2 vs. 2,259 173 cells/mm2, n 4 to 8, p 0.05)
Fig. 5C). In parallel, we observed reduced collagen content
n the infarcted area (Fig. 5D), corresponding to earlier
ndings in CCR2/ mice (19,20). In contrast, neutrophil/
-cell content, CCL2 expression, angiogenesis, apoptosis,
nd proliferation did not differ between the groups (data
ot shown). Unlike CCL2, PA508 did not induce dif-
erentiation of cultured fibroblasts into myofibroblasts (On-
ine Fig. 1F). These findings imply that, in addition to
educed monocyte infiltration, an alteration in scar myofi-
roblast and collagen content may account for improved
eart function, in particular at higher concentrations of
sion
ion system. Left ventricular developed pressure (LVDP) (A), maximum time-
asal function of the PA508 (10 g)–treated mice compared with control mice.
in PA508 (5 g)–treated and PA508 (10 g)–treated mice (left panel). All data
maximum pressure change over time.perfu
perfus
rved b
eters
t A508.
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therosclerotic cardiovascular disease with MI as its acute
linical manifestation is one of the leading causes of death
orldwide. Atherosclerosis is a chronic inflammation of the
rterial wall characterized by an influx of mononuclear cells
eleasing cytokines and chemokines, which in turn enhance
heir recruitment and activation (5,6). Acute MI also
riggers a complex inflammatory reaction orchestrated by
ytokines and chemokines, which cause monocyte recruit-
ent at sites of ischemic damage (3,4,32). Studies in animal
odels featuring an impaired monocyte infiltration consis-
ently yielded a reduction of neointima formation (13,17)
nd preserved heart function after experimental induction of
I (18–20). Therefore, interfering with monocyte recruit-
ent represents a valuable therapeutic strategy for future
linical use. The chemokine CCL2, one of the main factors
hat mediate recruitment of mononuclear cells, namely,
onocytes and T-cell subsets (12), modulates their pheno-
ype and regulates fibrous tissue deposition and angiogenesis
13). In a hyperlipidemic mouse model of acute arterial
njury, CCL2 rapidly up-regulated in the artery wall and
resented by surface-adherent platelets mediates early
onocyte arrest to denuded areas and subsequent neointima
ormation (17).
Here, we introduce the CCL2 competitor PA508 as a
herapeutic candidate for treating monocyte-driven inflam-
atory conditions, with a particular focus on cardiovascular
isease. Based on the concept that the interaction of
hemokines with GAGs and their presentation on the
urface of vascular endothelial cells or platelets are critical
or their function (5,17,33), the modified CCL2 variant
A508 displayed exceptionally high retention to GAGs yet
as functionally inactive, as shown by receptor binding,
hemotaxis, and calcium influx assays. In vitro, PA508
nhibited monocyte chemotaxis and transendothelial migra-
ion toward a CCL2 gradient, implying that presentation of
CL2 on both monocytes and endothelial cells is necessary
or efficient activation of CCR2. During the past decade, it
as become clear that GAGs are important cofactors for
In Vivo Assessment of Cardiac Function7 Days fter Myocardial Ischemia/ReperfusionTable 3 In Vivo Asses m nt of Cardiac Fu c7 Days After Myocardial Ischemia/
Sham
(n  6)
Echocardiography
Heart weight, mg 115 28
Heart rate, beats/min 476 66
Cardiac output, ml/min 11.6 5.1
Ejection fraction, % 61.9 6.4
Invasive measurement of cardiac function
Heart rate, beats/min 276 7
LVPD, mm Hg 107 5
dPdtmax, mm Hg/s 7,546 96
Value are mean  SEM.
dPdtmax  maximum pressure change over time; LVDP  left ventrhemokine receptor activation. For example, it has been ahown that CCR1 and CCR5 ligand binding and functional
ctivity were strongly reduced in the absence of GAGs on
hemokine receptor–expressing cells (34). Thus, a mecha-
ism can be envisioned where binding of a chemokine to
AGs takes place first and the chemokine receptor is
ctivated subsequently. As PA508 reduces the availability of
AGs for CCL2 through occupying its binding sites, the
et effect on CCR2 will be similar to an absence of GAGs.
When injected intraperitoneally into mice, PA508 rapidly
ntered the circulation, yet it did not influence circulating
evels of endogenous CCL2 nor cause any abnormalities in
erum liver and kidney parameters or organ histology. Thus,
A508 appears to be devoid of notable side effects. Treat-
ent with PA508 effectively reduced leukocyte recruitment
o air pouches in vivo and to injured atherosclerotic arteries
x vivo, suggesting that PA508 can actively cross-compete
ith endogenous CCL2 for binding sites on the vessel
urface despite its lower affinity for CCR2. Indeed, evidence
as recently provided that PA508 exhibits a 4-fold higher
ffinity toward the natural CCL2 GAG ligand heparan
ulfate and thereby displaces wild-type CCL2 from heparan
ulfate (23). Moreover, the absence of antagonistic activity
gainst, for example, CCL5 in vitro and in CCR2/ mice
n vivo indicates that PA508 specifically attenuates the
CL2-CCR2 axis, while leaving the functions of other
hemokines unaffected.
In the model of wire-induced neointimal hyperplasia, the
ffects of PA508 treatment on plaque formation were
omparable to those seen with CCR2-deficiency in Apoe/
ice (17), diminishing neointima formation and monocyte
nfiltration but increasing smooth muscle cell content. This
emonstrates the potential of the competitor to limit
eointimal growth and restenosis and to achieve a more
table, less inflammatory plaque phenotype after vascular
njury. Similarly, interference with chemokine oligomeriza-
ion and chemokine/heparin interactions using the chemo-
ine mutant [44AANA47]-CCL5 was recently reported as a
owerful approach to inhibit progression of established
rfusion
Control
(n  4)
PA508 (10 g)
(n  4)
p Value
PA508 vs. Control
69 7 76 8 NS
385 17 357 27 NS
10.2 1.0 10.4 2.0 NS
40.4 3.9 51.8 1.2 0.05
242 14 279 15 NS
64 5 86 6 0.05
3,061 404 4,834 393 0.05
eveloped pressure; other abbreviation as in Table 2.tion
Repe
9therosclerosis in mice, and through inhibiting leukocyte
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laque phenotype (35).
Previous work showed that CCL2 was markedly induced
fter MI and represented a key mediator of LV remodeling
uring the early phase of MI (20,36). CCL2-deficient mice
xhibited decreased monocyte recruitment to the infarcted
eart, attenuated fibroblast accumulation, and LV remod-
ling (19,20). Likewise, targeted deletion of CCR2 pro-
ected from development of adverse remodeling after MI
15,18). Here, we show that treatment of mice undergoing
yocardial I/R with the CCL2 competitor PA508 pre-
Figure 5 Histomorphometry and Scar Remodeling After Myocar
Paraffin-embedded hearts were cut in serial sections and stained with Gomori 1-st
vehicle-treated controls, PA508-treated mice (1, 5, or 10 g) show significantly sm
(B, arrows), whereas myofibroblast (C) and collagen (D) content was significantly
(6 to 8 mice per group, *p  0.05 vs. control).erved heart function and reduced MI size by inhibiting (yocardial macrophage–related inflammation, myofibro-
last infiltration, and subsequent collagen synthesis. It is
oteworthy that monocyte recruitment into the infarcted
rea of PA508-treated mice was markedly reduced, already
t the lowest dose administered. However, reduced mono-
yte infiltration alone does not appear to be sufficient to
mprove LV function. Therefore, additional effects of
CL2 unrelated to monocyte trafficking should be taken
nto account. We were able to show that, unlike CCL2,
A508 is unable to induce differentiation of fibroblasts into
yofibroblasts. By analogy to results in CCR2/ mice
schemia/Reperfusion
d heart wall and infarcted area were measured by planimetry (A). Compared with
nfarction size. Monocyte infiltration was drastically reduced in all treated groups
d only in PA508 (10 g)–treated mice. All data are reported as mean  SEMdial I
ep, an
aller i
reduce19,20), this, combined with inhibition of CCL2, may lead
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hich appears to be essential for improved heart function at
igher concentrations of PA508. On the other hand,
ecause PA508 limits the overall presentation and availabil-
ty of CCL2, in particular at higher doses, it is conceivable
hat the competitor may decrease exposure of cardiac
yocytes to CCL2, thereby reducing its potential apoptotic
ffects and contributing to cardiomyocyte survival and car-
iac viability (21).
Developing specific therapies against CCL2-mediated
nflammation is not limited to vascular diseases because
CL2 and its receptor play a critical role in many other
cute and chronic inflammatory diseases. Treatment of
CL2-mediated diseases has, however, not yet resulted in a
linically applicable product or therapeutically efficient drug
o date. Initially, promising biopharmaceutical approaches
ike the anti-CCL2 monoclonal antibody ABN912 (37) or
he P8A CCL2 mutant (11) showed no or insufficient
fficacy to reach final stages of drug development. On the
ther hand, small molecule CCR2 inhibitors remain in
ctive but still early development and, like the JNJ-
7141491 compound (38), may have significant advantages
ver biopharmaceuticals due to oral bioavailability. In gen-
ral, strategies that encompass the direct blockade of che-
okine receptors by small molecule antagonists have re-
urned rather disappointing results (39). The therapeutic
pproach presented here makes use of a novel way to
nterfere with CCL2 pathological activity by targeting the
AG coreceptor(s) of the chemokine. Engineering chemo-
ines to become protein-based GAG antagonists was out-
ined recently for CXCL8-related inflammatory diseases
40) and proved to work also in CCL5-related settings (41).
he CCL2-based PA508 mutant therefore represents a
ovel biologic for the treatment of pathological situations in
hich binding of CCL2 to GAGs is crucial for disease
nset or progression. On the other hand, potential side
ffects of PA508 on the immune system (e.g., during
CL2-mediated host defenses against infection with vi-
uses or parasites) should be carefully profiled and scruti-
ized (42–44).
onclusions
n summary, this study introduces an entirely new concept
y demonstrating favorable effects of the nonagonist CCL2
ompetitor PA508 in 2 mouse models for the most common
ascular diseases. Further pharmacological and clinical stud-
es in larger animal models and in humans are mandatory to
valuate and validate the therapeutic potential of PA508 as
n innovative drug for the treatment of vascular diseases.
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